| Year |
Citation |
Score |
| 2024 |
Tonelli C, Yordanov GN, Hao Y, Deschênes A, Hinds J, Belleau P, Klingbeil O, Brosnan E, Doshi A, Park Y, Hruban RH, Vakoc CR, Dobin A, Preall J, Tuveson DA. A mucus production programme promotes classical pancreatic ductal adenocarcinoma. Gut. PMID 38262672 DOI: 10.1136/gutjnl-2023-329839 |
0.352 |
|
| 2023 |
Xu J, Roe JS, Lee E, Tonelli C, Ji KY, Younis OW, Somervile TDD, Yao M, Milazzo JP, Tiriac H, Kolarzyk AM, Lee E, Grem JL, Lazenby AJ, Grunkemeyer JA, ... ... Tuveson DA, et al. Engrailed-1 Promotes Pancreatic Cancer Metastasis. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2308537. PMID 38110836 DOI: 10.1002/advs.202308537 |
0.72 |
|
| 2023 |
Amor C, Fernández-Maestre I, Chowdhury S, Ho YJ, Nadella S, Graham C, Carrasco SE, Nnuji-John E, Feucht J, Hinterleitner C, Barthet VJA, Boyer JA, Mezzadra R, Wereski MG, Tuveson DA, et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Research Square. PMID 37841853 DOI: 10.21203/rs.3.rs-3385749/v1 |
0.425 |
|
| 2023 |
Yao M, Preall J, Yeh J, Pappin DJ, Cifani P, Zhao Y, Shen S, Moresco P, He B, Patel H, Habowski AN, King DA, Raphael KL, Rishi A, Sejpal DV, ... ... Tuveson D, et al. Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies to self-antigens. Jci Insight. PMID 37751306 DOI: 10.1172/jci.insight.172449 |
0.771 |
|
| 2023 |
Wan L, Lin KT, Rahman MA, Ishigami Y, Wang Z, Jensen MA, Wilkinson JE, Park Y, Tuveson DA, Krainer AR. Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. Cancer Discovery. PMID 37098965 DOI: 10.1158/2159-8290.CD-22-1013 |
0.358 |
|
| 2023 |
Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: Perspectives and challenges. Cancer Cell. 41: 434-449. PMID 36917949 DOI: 10.1016/j.ccell.2023.02.015 |
0.336 |
|
| 2023 |
Yoo HB, Moon JW, Kim HR, Lee HS, Miyabayashi K, Park CH, Ge S, Zhang A, Tae YK, Sub Y, Park HW, Gee HY, Notta F, Tuveson DA, Bang S, et al. A TEAD2-driven endothelial-like program shapes basal-like differentiation and metastasis of pancreatic cancer. Gastroenterology. PMID 36907523 DOI: 10.1053/j.gastro.2023.02.049 |
0.334 |
|
| 2022 |
Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S, Barki D, Nevo R, Brown LE, Zhang W, Stein Y, Lior C, Kim HS, Bojmar L, Jarnagin WR, ... ... Tuveson DA, et al. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. Nature Communications. 13: 6513. PMID 36316305 DOI: 10.1038/s41467-022-34081-3 |
0.412 |
|
| 2022 |
Demyan L, Habowski AN, Plenker D, King DA, Standring OJ, Tsang C, St Surin L, Rishi A, Crawford JM, Boyd J, Pasha SA, Patel H, Galluzzo Z, Metz C, Gregersen PK, ... ... Tuveson DA, et al. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Annals of Surgery. 276: 450-462. PMID 35972511 DOI: 10.1097/SLA.0000000000005558 |
0.779 |
|
| 2022 |
De Sanctis F, Lamolinara A, Boschi F, Musiu C, Caligola S, Trovato R, Fiore A, Frusteri C, Anselmi C, Poffe O, Cestari T, Canè S, Sartoris S, Giugno R, Del Rosario G, ... ... Tuveson DA, et al. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Journal For Immunotherapy of Cancer. 10. PMID 35022194 DOI: 10.1136/jitc-2021-003549 |
0.352 |
|
| 2021 |
Hu T, Shukla SK, Vernucci E, He C, Wang D, King RJ, Jha K, Siddhanta K, Mullen NJ, Attri KS, Murthy D, Chaika NV, Thakur R, Mulder SE, Pacheco CG, ... ... Tuveson D, et al. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-induced Pancreatic Cancer Progression. Gastroenterology. PMID 34245764 DOI: 10.1053/j.gastro.2021.06.045 |
0.36 |
|
| 2021 |
Nielsen SR, Strøbech JE, Horton ER, Jackstadt R, Laitala A, Bravo MC, Maltese G, Jensen ARD, Reuten R, Rafaeva M, Karim SA, Hwang CI, Arnes L, Tuveson DA, Sansom OJ, et al. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nature Communications. 12: 3414. PMID 34099731 DOI: 10.1038/s41467-021-23731-7 |
0.727 |
|
| 2021 |
Cheng DK, Oni TE, Thalappillil JS, Park Y, Ting HC, Alagesan B, Prasad NV, Addison K, Rivera KD, Pappin DJ, Van Aelst L, Tuveson DA. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34021083 DOI: 10.1073/pnas.2016904118 |
0.325 |
|
| 2021 |
Steele NG, Biffi G, Kemp SB, Zhang Y, Drouillard D, Syu LJ, Hao Y, Oni TE, Brosnan E, Elyada E, Doshi A, Hansma C, Espinoza C, Abbas A, The S, ... ... Tuveson DA, et al. Inhibition of Hedgehog signaling alters fibroblast composition in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33495315 DOI: 10.1158/1078-0432.CCR-20-3715 |
0.691 |
|
| 2020 |
Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, ... ... Tuveson DA, et al. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nature Communications. 11: 5332. PMID 33087697 DOI: 10.1038/s41467-020-19141-w |
0.347 |
|
| 2020 |
Josselsohn RH, Tuveson DA. Pancreatic cancer SLUGged. The Journal of Experimental Medicine. 217. PMID 32813872 DOI: 10.1084/Jem.20200819 |
0.426 |
|
| 2020 |
Miyabayashi K, Baker LA, Deschenes A, Traub B, Caligiuri G, Plenker D, Alagesan B, Belleau P, Li S, Kendall J, Jang GH, Kawaguchi RK, Somerville TDD, Tiriac H, Hwang CI, ... ... Tuveson DA, et al. Intraductal transplantation models of human pancreatic ductal adenocarcinoma reveal progressive transition of molecular subtypes. Cancer Discovery. PMID 32703770 DOI: 10.1158/2159-8290.Cd-20-0133 |
0.748 |
|
| 2020 |
Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, et al. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery. PMID 32657929 DOI: 10.1097/Sla.0000000000004200 |
0.352 |
|
| 2020 |
Lau AN, Li Z, Danai LV, Westermark AM, Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM, Mayers JR, Biffi G, Chin CR, Davidson SM, Tuveson DA, et al. Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma. Elife. 9. PMID 32648540 DOI: 10.7554/Elife.56782 |
0.792 |
|
| 2020 |
Oni TE, Biffi G, Baker LA, Hao Y, Tonelli C, Somerville TDD, Deschênes A, Belleau P, Hwang CI, Sánchez-Rivera FJ, Cox H, Brosnan E, Doshi A, Lumia RP, Khaledi K, ... ... Tuveson DA, et al. SOAT1 promotes mevalonate pathway dependency in pancreatic cancer. The Journal of Experimental Medicine. 217. PMID 32633781 DOI: 10.1084/Jem.20192389 |
0.804 |
|
| 2020 |
Biffi G, Tuveson DA. DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. Physiological Reviews. PMID 32466724 DOI: 10.1152/Physrev.00048.2019 |
0.724 |
|
| 2020 |
Dasgupta A, Shukla SK, Vernucci E, King RJ, Abrego J, Mulder SE, Mullen NJ, Graves G, Buettner K, Thakur R, Murthy D, Attri KS, Wang D, Chaika NV, Pacheco CG, ... ... Tuveson DA, et al. SIRT1-NOX4 signaling axis regulates cancer cachexia. The Journal of Experimental Medicine. 217. PMID 32441762 DOI: 10.1084/Jem.20190745 |
0.418 |
|
| 2020 |
Janowitz T, Tuveson DA. The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research. Cancer Discovery. PMID 32404307 DOI: 10.1158/2159-8290.Cd-20-0657 |
0.356 |
|
| 2020 |
Corrie PG, Qian W, Basu B, Valle JW, Falk S, Lwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bridgewater J, Propper D, Gillmore R, Gopinathan A, ... ... Tuveson D, et al. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer. PMID 32350413 DOI: 10.1038/S41416-020-0846-2 |
0.359 |
|
| 2020 |
Somerville TD, Biffi G, Daßler-Plenker J, Hur SK, He XY, Vance KE, Miyabayashi K, Xu Y, Maia-Silva D, Klingbeil O, Demerdash OE, Preall JB, Hollingsworth MA, Egeblad M, Tuveson DA, et al. Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation. Elife. 9. PMID 32329713 DOI: 10.7554/Elife.53381 |
0.748 |
|
| 2020 |
Monje M, Borniger JC, D'Silva NJ, Deneen B, Dirks PB, Fattahi F, Frenette PS, Garzia L, Gutmann DH, Hanahan D, Hervey-Jumper SL, Hondermarck H, Hurov JB, Kepecs A, Knox SM, ... ... Tuveson DA, et al. Roadmap for the Emerging Field of Cancer Neuroscience. Cell. 181: 219-222. PMID 32302564 DOI: 10.1016/J.Cell.2020.03.034 |
0.395 |
|
| 2020 |
Mardis ER, Ribas A, Hait WN, Jaffee EM, Foti M, Abate-Shen C, Albini A, Bernards R, Cruz-Correa MR, Flaherty KT, Greenberg PD, June CH, Knudsen KE, Liu ET, Mills GB, ... ... Tuveson DA, et al. AACR calls on congress to take immediate action against COVID-19 and protect patients with cancer during the pandemic Cancer Discovery. 10: 771-774. PMID 32295764 DOI: 10.1158/2159-8290.Cd-20-0449 |
0.369 |
|
| 2020 |
LaComb JF, Plenker D, Tiriac H, Bucobo JC, D'Souza LS, Khokhar AS, Patel H, Channer B, Joseph D, Wu M, Tuveson DA, Li E, Buscaglia JM. Single-Pass vs 2-Pass Endoscopic Ultrasound-guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 32119924 DOI: 10.1016/J.Cgh.2020.02.045 |
0.303 |
|
| 2020 |
Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, Askan G, Bhanot U, Elyada E, Park Y, Tuveson DA, et al. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. PMID 32076273 DOI: 10.1038/S41586-020-2015-4 |
0.363 |
|
| 2020 |
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J, Wilson JM, Jang GH, Zhang A, Liang SB, Borgida A, ... ... Tuveson DA, et al. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Genetics. PMID 32051610 DOI: 10.1038/S41588-020-0588-3 |
0.407 |
|
| 2020 |
Tian C, Öhlund D, Rickelt S, Lidström T, Huang Y, Hao L, Zhao RT, Franklin O, Bhatia SN, Tuveson DA, Hynes RO. Cancer-cell-derived matrisome proteins promote metastasis in pancreatic ductal adenocarcinoma. Cancer Research. PMID 32029550 DOI: 10.1158/0008-5472.Can-19-2578 |
0.483 |
|
| 2020 |
Cheung EC, DeNicola GM, Nixon C, Blyth K, Labuschagne CF, Tuveson DA, Vousden KH. Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer. Cancer Cell. PMID 31983610 DOI: 10.1016/J.Ccell.2019.12.012 |
0.7 |
|
| 2020 |
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, ... ... Tuveson DA, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews. Cancer. PMID 31980749 DOI: 10.1038/S41568-019-0238-1 |
0.432 |
|
| 2020 |
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J, Wilson JM, Jang GH, Zhang A, Liang SB, Borgida A, ... ... Tuveson DA, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Genetics. PMID 31932696 DOI: 10.1038/S41588-019-0566-9 |
0.386 |
|
| 2020 |
Lau AN, Li Z, Danai LV, Westermark AM, Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM, Mayers JR, Biffi G, Chin CR, Davidson SM, Tuveson DA, et al. Author response: Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma Elife. DOI: 10.7554/Elife.56782.Sa2 |
0.751 |
|
| 2020 |
Somerville TD, Biffi G, Daßler-Plenker J, Hur SK, He X, Vance KE, Miyabayashi K, Xu Y, Maia-Silva D, Klingbeil O, Demerdash OE, Preall JB, Hollingsworth MA, Egeblad M, Tuveson DA, et al. Author response: Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation Elife. DOI: 10.7554/Elife.53381.Sa2 |
0.713 |
|
| 2020 |
Perez K, Cleary JM, Karasic TB, Raghavan S, Rahma OE, Nowak J, Borazanci EH, Downes M, Drebin JA, Tuveson DA, Ting DT, Moffitt R, Yeh JJ, Aguirre A, Evans R, et al. Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 38: TPS784-TPS784. DOI: 10.1200/Jco.2020.38.4_Suppl.Tps784 |
0.392 |
|
| 2020 |
Froeling FE, Robine N, Hubert B, Zody M, Oschwald D, Varmus HE, Sawyers CL, Tuveson DA. Abstract 5128: Polyethnic-1000: Advancing cancer genomics by studying ethnically diverse, underserved patient populations in New York Cancer Research. 79: 5128-5128. DOI: 10.1158/1538-7445.Am2019-5128 |
0.549 |
|
| 2019 |
Bott AJ, Shen J, Tonelli C, Zhan L, Sivaram N, Jiang YP, Yu X, Bhatt V, Chiles E, Zhong H, Maimouni S, Dai W, Velasquez S, Pan JA, Muthalagu N, ... ... Tuveson DA, et al. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Cell Reports. 29: 1287-1298.e6. PMID 31665640 DOI: 10.1016/J.Celrep.2019.09.056 |
0.463 |
|
| 2019 |
Froeling FEM, Mosur Swamynathan M, Deschênes A, Chio IIC, Brosnan E, Yao MA, Alagesan P, Lucito MS, Li J, Chang AY, Trotman LC, Belleau P, Park Y, Rogoff HA, Watson JD, ... Tuveson DA, et al. Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31527169 DOI: 10.1158/1078-0432.Ccr-19-0302 |
0.352 |
|
| 2019 |
Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang CI, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang PS, Smith PD, ... ... Tuveson DA, et al. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31492749 DOI: 10.1158/1078-0432.Ccr-19-1398 |
0.745 |
|
| 2019 |
Tian C, Clauser KR, Öhlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, Hynes RO. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 31484774 DOI: 10.1073/Pnas.1908626116 |
0.464 |
|
| 2019 |
Mirabelli CK, Nusse R, Tuveson DA, Williams BO. Perspectives on the role of Wnt biology in cancer. Science Signaling. 12. PMID 31289213 DOI: 10.1126/Scisignal.Aay4494 |
0.582 |
|
| 2019 |
Humpton TJ, Alagesan B, DeNicola GM, Lu D, Yordanov GN, Leonhardt CS, Yao MA, Alagesan P, Zaatari MN, Park Y, Skepper JN, Macleod KF, Perez-Mancera PA, Murphy MP, Evan GI, ... ... Tuveson DA, et al. Oncogenic Kras induces Nix-mediated mitophagy to promote pancreatic cancer. Cancer Discovery. PMID 31263025 DOI: 10.1158/2159-8290.Cd-18-1409 |
0.781 |
|
| 2019 |
Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, Lalani AS, Tuveson D, Martinez J, Hancock JF. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. PMID 31253872 DOI: 10.1038/S41388-019-0849-8 |
0.387 |
|
| 2019 |
Sugarman R, Patel R, Sharma S, Plenker D, Tuveson D, Saif MW. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opinion On Drug Metabolism & Toxicology. PMID 31241371 DOI: 10.1080/17425255.2019.1637417 |
0.451 |
|
| 2019 |
Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, ... ... Tuveson DA, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science (New York, N.Y.). 364: 1156-1162. PMID 31221853 DOI: 10.1126/Science.Aaw3145 |
0.344 |
|
| 2019 |
Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, ... ... Tuveson DA, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discovery. PMID 31197017 DOI: 10.1158/2159-8290.Cd-19-0094 |
0.7 |
|
| 2019 |
Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science (New York, N.Y.). 364: 952-955. PMID 31171691 DOI: 10.1126/Science.Aaw6985 |
0.456 |
|
| 2019 |
Driehuis E, Kolders S, Spelier S, Lohmussaar K, Willems SM, Devriese LA, de Bree R, de Ruiter EJ, Korving J, Begthel H, Van Es JH, Geurts V, He GW, van Jaarsveld RH, Oka R, ... ... Tuveson DA, et al. Oral mucosal organoids as a potential platform for personalized cancer therapy. Cancer Discovery. PMID 31053628 DOI: 10.1158/2159-8290.Cd-18-1522 |
0.347 |
|
| 2019 |
Biffi G, Tuveson DA. A FATal Combination: Fibroblast-Derived Lipids and Cancer-Derived Autotaxin Promote Pancreatic Cancer Growth. Cancer Discovery. 9: 578-580. PMID 31043410 DOI: 10.1158/2159-8290.Cd-19-0273 |
0.731 |
|
| 2019 |
Tiriac H, Plenker D, Baker LA, Tuveson DA. Organoid models for translational pancreatic cancer research. Current Opinion in Genetics & Development. 54: 7-11. PMID 30844513 DOI: 10.1016/J.Gde.2019.02.003 |
0.458 |
|
| 2019 |
Baker LA, Tuveson DA. Generation and Culture of Tumor and Metastatic Organoids from Murine Models of Pancreatic Ductal Adenocarcinoma. Methods in Molecular Biology (Clifton, N.J.). 1882: 117-133. PMID 30378048 DOI: 10.1007/978-1-4939-8879-2_10 |
0.396 |
|
| 2019 |
Baker LA, Tiriac H, Tuveson DA. Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens. Methods in Molecular Biology (Clifton, N.J.). 1882: 97-115. PMID 30378047 DOI: 10.1007/978-1-4939-8879-2_9 |
0.419 |
|
| 2019 |
Engle D, Tiriac H, Rivera K, Pommier A, Whalen S, Oni T, Alagesan B, Lee E, Yao M, Lucito M, Spielman B, Yu K, Grutzmann R, Aust D, Gimotty P, ... ... Tuveson D, et al. Abstract PR12: The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-Pr12 |
0.383 |
|
| 2019 |
Tiriac H, Belleau P, Engle D, Plenker D, Deschenes A, Somerville T, Froeling F, Moffitt R, Knox J, Krasnitz A, Gallinger S, Tuveson D. Abstract C57: Organoid profiling identifies common responders to chemotherapy in pancreatic cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-C57 |
0.475 |
|
| 2019 |
Hwang C, Roe J, Lee EJ, Tonelli C, Somervile TDD, Yao M, Milazzo JP, Tiriac H, Park Y, Vakoc C, Tuveson D. Abstract B25: Engrailed-1 promotes pancreatic cancer progression via antagonizing COMPASS activity Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B25 |
0.784 |
|
| 2019 |
Leung J, Rojas LA, Ruan J, Zhao J, Gasmi B, Sethna Z, Ramnarain A, Bhanot U, Askan G, Gururajan M, Elyada E, Park Y, Tuveson DA, Gonen M, Leach SD, et al. Abstract B02: Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-B02 |
0.427 |
|
| 2019 |
Clevers H, Tuveson DA. Organoid Models for Cancer Research Annual Review of Cancer Biology. 3: 223-234. DOI: 10.1146/ANNUREV-CANCERBIO-030518-055702 |
0.314 |
|
| 2018 |
Biffi G, Tuveson DA. Deciphering cancer fibroblasts. The Journal of Experimental Medicine. PMID 30470718 DOI: 10.1084/Jem.20182069 |
0.676 |
|
| 2018 |
Somerville TDD, Xu Y, Miyabayashi K, Tiriac H, Cleary CR, Maia-Silva D, Milazzo JP, Tuveson DA, Vakoc CR. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma. Cell Reports. 25: 1741-1755.e7. PMID 30428345 DOI: 10.1016/J.Celrep.2018.10.051 |
0.444 |
|
| 2018 |
Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J, Tuveson DA. IL-1-induced JAK/STAT signaling is antagonized by TGF-beta to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discovery. PMID 30366930 DOI: 10.1158/2159-8290.Cd-18-0710 |
0.67 |
|
| 2018 |
Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. PMID 30177543 DOI: 10.1136/Gutjnl-2018-316451 |
0.422 |
|
| 2018 |
Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, ... ... Tuveson DA, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discovery. PMID 29903880 DOI: 10.1158/2159-8290.Cd-18-0275 |
0.343 |
|
| 2018 |
Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville T, Froeling FEM, Burkhart RA, Denroche RE, Jang GH, Miyabayashi K, Young CM, Patel H, Ma M, LaComb JF, ... ... Tuveson DA, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discovery. PMID 29853643 DOI: 10.1158/2159-8290.Cd-18-0349 |
0.456 |
|
| 2018 |
Schmid MC, Quaranta V, Rainer C, Nielsen SR, Raymant ML, Ahmed MS, Engle DD, Taylor A, Murray T, Campbell F, Palmer DH, Tuveson DA, Mielgo A. Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer. Cancer Research. PMID 29789416 DOI: 10.1158/0008-5472.Can-17-3876 |
0.419 |
|
| 2018 |
Froeling F, Tuveson D. Pancreatic cancer foiled by a switch of tumour subtype. Nature. 557: 500-501. PMID 29777189 DOI: 10.1038/D41586-018-05129-6 |
0.401 |
|
| 2018 |
Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, ... ... Tuveson D, et al. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 9: 14764-14790. PMID 29599906 DOI: 10.18632/Oncotarget.24483 |
0.388 |
|
| 2018 |
Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, Palmer D, Propper D, Venugopal B, Hategan M, Anthoney DA, Hampson LV, Nebozhyn M, Tuveson D, Farmer-Hall H, et al. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer. PMID 29438372 DOI: 10.1038/Bjc.2017.495 |
0.433 |
|
| 2018 |
Aberle MR, Burkhart RA, Tiriac H, Olde Damink SWM, Dejong CHC, Tuveson DA, van Dam RM. Patient-derived organoid models help define personalized management of gastrointestinal cancer. The British Journal of Surgery. 105: e48-e60. PMID 29341164 DOI: 10.1002/Bjs.10726 |
0.381 |
|
| 2018 |
Tiriac H, Bucobo JC, Tzimas D, Grewel S, Lacomb JF, Rowehl LM, Nagula S, Wu M, Kim J, Sasson A, Vignesh S, Martello L, Munoz-Sagastibelza M, Somma J, Tuveson DA, et al. Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy for personalized cancer treatment. Gastrointestinal Endoscopy. PMID 29325707 DOI: 10.1016/J.Gie.2017.12.032 |
0.468 |
|
| 2018 |
Cheng D, Tuveson D. Kras in Organoids. Cold Spring Harbor Perspectives in Medicine. PMID 29311127 DOI: 10.1101/Cshperspect.A031575 |
0.435 |
|
| 2018 |
Engle D, Tiriac H, Pommier A, Schoepfer C, Silva BD, Yao M, Park Y, Hollingsworth MA, Tuveson D. Abstract A27: Exploring the role of glycosylation in pancreatic disease Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-A27 |
0.334 |
|
| 2017 |
Vakoc CR, Tuveson DA. Soils and Seeds That Initiate Pancreatic Cancer Metastasis. Cancer Discovery. 7: 1067-1068. PMID 28974531 DOI: 10.1158/2159-8290.Cd-17-0887 |
0.456 |
|
| 2017 |
Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriac H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, ... ... Tuveson DA, et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. PMID 28757253 DOI: 10.1016/J.Cell.2017.07.007 |
0.737 |
|
| 2017 |
Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nature Genetics. PMID 28481342 DOI: 10.1038/Ng.3861 |
0.373 |
|
| 2017 |
Chio IIC, Tuveson DA. ROS in Cancer: The Burning Question. Trends in Molecular Medicine. PMID 28427863 DOI: 10.1016/J.Molmed.2017.03.004 |
0.416 |
|
| 2017 |
Sacristán C, Tuveson DA. Quid pro Quo: A Tumor is Not Alone. Trends in Molecular Medicine. PMID 28408271 DOI: 10.1016/J.Molmed.2017.03.007 |
0.471 |
|
| 2017 |
Sinha S, Fu YY, Grimont A, Ketcham M, Lafaro K, Saglimbeni JA, Askan G, Bailey JM, Melchor JP, Zhong Y, Joo MG, Grbovic-Huezo O, Yang IH, Basturk O, Baker L, ... ... Tuveson D, et al. PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk. Cancer Research. PMID 28386018 DOI: 10.1158/0008-5472.CAN-16-0899-T |
0.308 |
|
| 2017 |
Tuveson D. Waging war against pancreatic cancer: an interview with David Tuveson. Disease Models & Mechanisms. 10: 353-357. PMID 28381597 DOI: 10.1242/Dmm.029975 |
0.456 |
|
| 2017 |
Feigin ME, Tuveson DA. Challenges and Opportunities in Modeling Pancreatic Cancer. Cold Spring Harbor Symposia On Quantitative Biology. PMID 28289164 DOI: 10.1101/Sqb.2016.81.031104 |
0.456 |
|
| 2017 |
Vakoc CR, Tuveson DA. Untangling the genetics from the epigenetics in pancreatic cancer metastasis. Nature Genetics. 49: 323-324. PMID 28232730 DOI: 10.1038/Ng.3798 |
0.474 |
|
| 2017 |
Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, ... ... Tuveson DA, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. The Journal of Experimental Medicine. PMID 28232471 DOI: 10.1084/Jem.20162024 |
0.819 |
|
| 2017 |
Sinha S, Fu YY, Grimont A, Ketcham M, Lafaro KJ, Saglimbeni JA, Askan G, Bailey JM, Melchor JP, Zhong Y, Joo MG, Grbovic-Huezo O, Yang IH, Basturk O, Baker L, ... ... Tuveson DA, et al. PanIN neuroendocrine cells promote tumorigenesis via neuronal crosstalk. Cancer Research. PMID 28104683 DOI: 10.1158/0008-5472.Can-16-0899 |
0.405 |
|
| 2017 |
Biffi G, Tuveson DA. Cancer: Double trouble for tumours. Nature. PMID 28099410 DOI: 10.1038/Nature21117 |
0.7 |
|
| 2017 |
Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Ohlund D, Hammell M, Crawford H, Schmidt E, Thompson C, Pappin D, Sonenberg N, Tuveson D. Abstract PR03: NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Transcontrol16-Pr03 |
0.482 |
|
| 2017 |
Aguirre AJ, Carter S, Camarda N, Ghazani A, Nowak J, Silva AD, Brais L, Ragon D, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Shyn P, ... ... Tuveson D, et al. Abstract 3036: Real-time genomic characterization of metastatic pancreatic cancer to enable precision medicine Cancer Research. 77: 3036-3036. DOI: 10.1158/1538-7445.Am2017-3036 |
0.392 |
|
| 2017 |
Corrie P, Qian W, Gopinathan A, Williams M, Brais R, Valle J, Basu B, Falk S, Iwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J, Arif S, Bax L, ... ... Tuveson D, et al. Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) Annals of Oncology. 28: v251-v252. DOI: 10.1093/Annonc/Mdx369.121 |
0.322 |
|
| 2016 |
Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera P, Coupland SE, Taktak AF, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Research. PMID 27742686 DOI: 10.1158/0008-5472.Can-16-1201 |
0.437 |
|
| 2016 |
Chio II, Tuveson DA. ROS in translation: chink in the armor. Cell Cycle (Georgetown, Tex.). 0. PMID 27636545 DOI: 10.1080/15384101.2016.1232087 |
0.435 |
|
| 2016 |
Chio II, Jafarnejad SM, Ponz-Sarvise M, Park Y, Rivera K, Palm W, Wilson J, Sangar V, Hao Y, Öhlund D, Wright K, Filippini D, Lee EJ, Da Silva B, Schoepfer C, ... ... Tuveson DA, et al. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Cell. PMID 27477511 DOI: 10.1016/J.Cell.2016.06.056 |
0.728 |
|
| 2016 |
Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, et al. Corrigendum: Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology. 18: 822. PMID 27350447 DOI: 10.1038/Ncb3377 |
0.389 |
|
| 2016 |
Boj SF, Hwang CI, Baker LA, Engle DD, Tuveson DA, Clevers H. Model organoids provide new research opportunities for ductal pancreatic cancer. Molecular & Cellular Oncology. 3: e1014757. PMID 27308531 DOI: 10.1080/23723556.2015.1014757 |
0.745 |
|
| 2016 |
Biffi G, Öhlund D, Tuveson D. Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. Cell Death and Differentiation. 23: 1265-6. PMID 27285108 DOI: 10.1038/Cdd.2016.50 |
0.663 |
|
| 2016 |
Ohman KA, Hashim YM, Vangveravong S, Nywening TM, Cullinan DR, Goedegebuure SP, Liu J, Van Tine BA, Tiriac H, Tuveson DA, DeNardo DG, Spitzer D, Mach RH, Hawkins WG. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget. PMID 27244881 DOI: 10.18632/Oncotarget.9551 |
0.44 |
|
| 2016 |
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nature Reviews. Disease Primers. 2: 16022. PMID 27158978 DOI: 10.1038/nrdp.2016.22 |
0.376 |
|
| 2016 |
Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling pancreatic cancer with organoids. Trends in Cancer. 2: 176-190. PMID 27135056 DOI: 10.1016/J.Trecan.2016.03.004 |
0.375 |
|
| 2016 |
Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer D, Ko JH, Tuveson DA, et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology. PMID 27088855 DOI: 10.1038/Ncb3340 |
0.362 |
|
| 2016 |
Espana-Agusti J, Zou X, Wong K, Fu B, Yang F, Tuveson DA, Adams DJ, Matakidou A. Generation and Characterisation of a Pax8-CreERT2 Transgenic Line and a Slc22a6-CreERT2 Knock-In Line for Inducible and Specific Genetic Manipulation of Renal Tubular Epithelial Cells. Plos One. 11: e0148055. PMID 26866916 DOI: 10.1371/Journal.Pone.0148055 |
0.301 |
|
| 2016 |
Tuveson D. Organoids to study and stop pancreatic cancer Hamdan Medical Journal. 9: 311. DOI: 10.7707/hmj.694 |
0.346 |
|
| 2016 |
Tuveson D. Experimental approaches to ductal pancreatic cancer Hamdan Medical Journal. 9: 277. DOI: 10.7707/hmj.693 |
0.307 |
|
| 2016 |
Ricigliano M, Cooper B, Ocean AJ, Tiriac H, Tuveson DA, Yu KH, O'Reilly EM. Expression levels of aldehyde dehydrogenase 1A1 (ALDH1A1) in circulating tumor and invasive cells (CTICs) as a biomarker for drug resistance and disulfiram in pancreatic adenocarcinoma (PDAC). Journal of Clinical Oncology. 34: e15755-e15755. DOI: 10.1200/Jco.2016.34.15_Suppl.E15755 |
0.405 |
|
| 2016 |
Zaaroor M, Sinai A, Goldsher D, Eran A, Nassar M, Schlesinger I, Parker J, Ravikumar V, Ghanouni P, Stein S, Halpern C, Krishna V, Hargrove A, Agrawal P, Changizi B, ... ... Tuveson D, et al. 5th International Symposium on Focused Ultrasound Journal of Therapeutic Ultrasound. 4. DOI: 10.1186/S40349-016-0076-5 |
0.633 |
|
| 2016 |
Baker LA, Tiriac H, Corbo V, Boj SF, Hwang C, Chio IIC, Engle DD, Jager M, Ponz-Sarvise M, Spector MS, Gracanin A, Oni T, Yu KH, Boxtel Rv, Huch M, ... ... Tuveson DA, et al. Abstract B16: Using human patient-derived organoids to identify genetic dependencies in pancreatic cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B16 |
0.829 |
|
| 2016 |
Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. Abstract B43: The utilization of extracellular proteins as nutrients is suppressed by mTORC1 Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-B43 |
0.345 |
|
| 2016 |
Chio IIC, Jafarnejad SM, Ponz-Sarvise M, Rivera K, Öhlund D, Sangar V, Wright K, Fillippi D, Hao Y, Wilkinson JE, Tiriac H, Hammell M, Schmidt E, Park Y, Pappin D, ... ... Tuveson D, et al. Abstract PR04: Nrf2 promotes mRNA translation in pancreatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-Pr04 |
0.468 |
|
| 2016 |
Tuveson D. Abstract IA11: Pancreatic cancer biology and medicine Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-Ia11 |
0.533 |
|
| 2016 |
Öhlund D, Handly-Santana A, Elyada E, Biffi G, Tuveson DA. Abstract B73: Pancreatic stellate cell heterogeneity in cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B73 |
0.705 |
|
| 2016 |
Tiriac H, Ponz-Sarvise M, Corbo V, Frese KK, Engle DD, Ohlund D, Oni T, Hwang C, Handly-Santana A, Alagesan B, Filippini D, Wright K, Yu KH, Park Y, Tuveson DA. Abstract B64: Using pancreatic organoids to infer therapeutic resistance and sensitivity Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B64 |
0.68 |
|
| 2016 |
DeNicola GM, Chen P, Mullarky E, Chio C, Asara JM, Minna JD, Tuveson DA, DeBerardinis RJ, Cantley LC. Abstract B04: NRF2 regulates serine biosynthesis in pancreatic ductal adenocarcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B04 |
0.761 |
|
| 2016 |
Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, Tuveson DA. Abstract A27: Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-A27 |
0.317 |
|
| 2016 |
Oni TE, Bautista C, Nelson B, Tuveson DA. Abstract A06: Identification of tumor-specific antibodies using phage display selections on pancreatic ductal organoids Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-A06 |
0.441 |
|
| 2016 |
Engle D, Tiriac H, Keith R, Ludwig M, Hwang C, Yu K, Pappin D, Tuveson D. Abstract A04: Identification of novel pancreatic cancer-specific biomarkers with organoid models Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-A04 |
0.741 |
|
| 2016 |
Hwang C, Lee E, Silva BD, Wright K, Park Y, Tuveson DA. Abstract 1027: Development of orthotopically grafted organoid models to study pancreatic cancer progression Cancer Research. 76: 1027-1027. DOI: 10.1158/1538-7445.Am2017-1027 |
0.736 |
|
| 2016 |
Ponz-Sarvise M, Corbo V, Frese K, Tiriac H, Engle D, Filipini D, Wright K, Park Y, Yu K, Daniel Ö, Tuveson D. Using mouse and human pancreatic organoids to infer resistance to targeted therapy Annals of Oncology. 27: vi527. DOI: 10.1093/Annonc/Mdw392.05 |
0.314 |
|
| 2016 |
Öhlund D, Handly-Santana A, Elyada E, Biffi G, Tuveson DA. Pancreatic stellate cell heterogeneity in cancer Pancreatology. 16: S15. DOI: 10.1016/J.Pan.2016.05.055 |
0.73 |
|
| 2015 |
Jenkinson C, Elliott V, Evans A, Oldfield L, Jenkins RE, O'Brien DP, Apostolidou S, Gentry-Maharaj A, Fourkala EO, Jacobs I, Menon U, Cox TF, Campbell F, Pereira SP, Tuveson DA, et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26573598 DOI: 10.1158/1078-0432.Ccr-15-0879 |
0.341 |
|
| 2015 |
Rosati A, Basile A, D'Auria R, d'Avenia M, De Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, ... ... Tuveson DA, et al. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nature Communications. 6: 8695. PMID 26522614 DOI: 10.1038/Ncomms9695 |
0.423 |
|
| 2015 |
Zambirinis CP, Levie E, Nguy S, Avanzi A, Barilla R, Xu Y, Seifert L, Daley D, Greco SH, Deutsch M, Jonnadula S, Torres-Hernandez A, Tippens D, Pushalkar S, Eisenthal A, ... ... Tuveson D, et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. The Journal of Experimental Medicine. PMID 26481685 DOI: 10.1084/Jem.20142162 |
0.406 |
|
| 2015 |
Hwang CI, Boj SF, Clevers H, Tuveson DA. Pre-clinical Models of Pancreatic Ductal Adenocarcinoma. The Journal of Pathology. PMID 26419819 DOI: 10.1002/Path.4651 |
0.736 |
|
| 2015 |
Serrao EM, Kettunen MI, Rodrigues TB, Dzien P, Wright AJ, Gopinathan A, Gallagher FA, Lewis DY, Frese KK, Almeida J, Howat WJ, Tuveson DA, Brindle KM. MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut. PMID 26347531 DOI: 10.1136/Gutjnl-2015-310114 |
0.39 |
|
| 2015 |
Ponz-Sarvise M, Tuveson DA, Yu KH. Mouse Models of Pancreatic Ductal Adenocarcinoma. Hematology/Oncology Clinics of North America. 29: 609-617. PMID 26226900 DOI: 10.1016/J.Hoc.2015.04.010 |
0.381 |
|
| 2015 |
Palm W, Park Y, Wright K, Pavlova NN, Tuveson DA, Thompson CB. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. Cell. 162: 259-70. PMID 26144316 DOI: 10.1016/J.Cell.2015.06.017 |
0.313 |
|
| 2015 |
Neesse A, Algül H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. PMID 25994217 DOI: 10.1136/Gutjnl-2015-309304 |
0.414 |
|
| 2015 |
Schlomann U, Koller G, Conrad C, Ferdous T, Golfi P, Garcia AM, Höfling S, Parsons M, Costa P, Soper R, Bossard M, Hagemann T, Roshani R, Sewald N, Ketchem RR, ... ... Tuveson DA, et al. ADAM8 as a drug target in pancreatic cancer. Nature Communications. 6: 6175. PMID 25629724 DOI: 10.1038/Ncomms7175 |
0.446 |
|
| 2015 |
Perna D, Karreth FA, Rust AG, Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ, Bosenberg MW, Bollag G, Tuveson DA, Adams DJ. BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America. 112: E536-45. PMID 25624498 DOI: 10.1073/Pnas.1418163112 |
0.391 |
|
| 2015 |
Saiyin H, Ardito-Abraham CM, Wu Y, Wei Y, Fang Y, Han X, Li J, Zhou P, Yi Q, Maitra A, Liu JO, Tuveson DA, Lou W, Yu L. Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma. The Journal of Pathology. 236: 142-54. PMID 25561062 DOI: 10.1002/Path.4506 |
0.331 |
|
| 2015 |
Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvise M, Tiriac H, Spector MS, Gracanin A, Oni T, Yu KH, van Boxtel R, Huch M, ... ... Tuveson DA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 160: 324-38. PMID 25557080 DOI: 10.1016/J.Cell.2014.12.021 |
0.826 |
|
| 2015 |
Fearon DT, Pommier A, Ludwig M, Tuveson D. Abstract IA11: T cell exclusion in pancreatic ductal adenocarcinoma: The FAP+ cancer-associated fibroblast and CXCL12 Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Ia11 |
0.441 |
|
| 2015 |
Carapuça EF, Gemenetzidis E, Feig C, Tuveson D, Kocher H. Abstract B72: Developing drug combinations to co-target pancreatic cancer and its supporting stroma Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B72 |
0.509 |
|
| 2015 |
Roy I, McAllister D, Gorse E, Dixon K, Cheng G, Getschman A, Engle D, Tsai S, Tuveson D, Evans D, Volkman B, Kalyanaraman B, Dwinell M. Abstract B55: Chemokine biased agonists regulate pancreatic cancer migration and metastasis through bioenergetic signaling Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-B55 |
0.418 |
|
| 2015 |
Tian C, Olund D, Tuveson D, Hynes RO. Abstract A45: Understanding the roles of extracellular matrix proteins in pancreatic ductal adenocarcinoma progression and metastasis Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A45 |
0.459 |
|
| 2015 |
Rosati A, Basile A, D'Auria R, d'Avenia M, Marco MD, Falco A, Festa M, Guerriero L, Iorio V, Pascale M, Franco R, Arra C, Barbieri A, Rea D, Menichini G, ... ... Tuveson DA, et al. Abstract 2393: PDAC cells release BAG3 that activates a paracrine loop with stromal macrophages Cancer Research. 75: 2393-2393. DOI: 10.1158/1538-7445.Am2015-2393 |
0.471 |
|
| 2015 |
Tian C, Ohlund D, Clauser K, Carr SA, Tuveson DA, Hynes RO. Abstract 1819: Profiling of extracellular matrix proteins in pancreatic ductal adenocarcinoma progression and metastasis Cancer Research. 75: 1819-1819. DOI: 10.1158/1538-7445.Am2015-1819 |
0.429 |
|
| 2015 |
Tuveson DA. Abstract PL03-03: K-RAS dependency in pancreatic cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Pl03-03 |
0.493 |
|
| 2015 |
Jenkinson C, Elliott V, Evans A, Oldfield L, O'Brien D, Apostolidou S, Gentry-Maharaj A, Fourkala E, Jacobs I, Menon U, Cox T, Campbell F, Tuveson D, Greenhalf W, Sutton R, et al. Decreased serum thrombospondin-1 levels in pancreatic ductal adenocarcinoma patients: an early indicator of disease or diabetes mellitus development? Pancreatology. 15: S28. DOI: 10.1016/J.Pan.2015.05.129 |
0.321 |
|
| 2014 |
Chio IIC, Yordanov G, Tuveson DA. MAX-ing out MYC: A novel small molecule inhibitor against MYC-dependent tumors Journal of the National Cancer Institute. 106. PMID 25430851 DOI: 10.1093/Jnci/Dju365 |
0.464 |
|
| 2014 |
Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, ... ... Tuveson DA, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 159: 80-93. PMID 25259922 DOI: 10.1016/J.Cell.2014.08.007 |
0.438 |
|
| 2014 |
Corbo V, Ponz-Sarvise M, Tuveson DA. The RAS and YAP1 dance, who is leading? The Embo Journal. 33: 2437-8. PMID 25257311 DOI: 10.15252/Embj.201490014 |
0.313 |
|
| 2014 |
Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, Jiang P, Li X, Thompson CB, Infante JR, Jacobetz MA, Tuveson DA, Frost GI, Shepard HM, Huang Z. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Research International. 2014: 817613. PMID 25147816 DOI: 10.1155/2014/817613 |
0.483 |
|
| 2014 |
Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound Journal of Experimental Medicine. 211: 1503-1523. PMID 25071162 DOI: 10.1084/Jem.20140692 |
0.454 |
|
| 2014 |
Chandel NS, Tuveson DA. The promise and perils of antioxidants for cancer patients. The New England Journal of Medicine. 371: 177-8. PMID 25006725 DOI: 10.1056/Nejmcibr1405701 |
0.363 |
|
| 2014 |
Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. British Journal of Cancer. 111: 318-25. PMID 24874484 DOI: 10.1038/Bjc.2014.288 |
0.429 |
|
| 2014 |
Davies CC, Harvey E, McMahon RFT, Finegan KG, Connor F, Davis RJ, Tuveson DA, Tournier C. Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma Cancer Research. 74: 3344-3356. PMID 24713432 DOI: 10.1016/J.Pan.2015.05.156 |
0.417 |
|
| 2014 |
Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, Reinecke J, Nikorowitsch J, Brunner M, Singh G, Fernandez-Zapico ME, ... ... Tuveson D, et al. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discovery. 4: 688-701. PMID 24694735 DOI: 10.1158/2159-8290.Cd-13-0593 |
0.467 |
|
| 2014 |
Neesse A, Michl P, Tuveson DA, Ellenrieder V. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Zeitschrift FüR Gastroenterologie. 52: 360-6. PMID 24687799 DOI: 10.1055/S-0034-1366002 |
0.453 |
|
| 2014 |
Cook N, Basu B, Smith D, Gopinathan A, Evans TJ, Steward WP, Hagemann T, Venugopal B, Tuveson DA, Hategan M, Anthoney DA, Farmer H, Turner H, McLeod R, Halford SER, et al. A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 32: 4116-4116. DOI: 10.1200/Jco.2014.32.15_Suppl.4116 |
0.345 |
|
| 2014 |
Tuveson D. Abstract IA11: Progress in pancreatic cancer modeling Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Ia11 |
0.555 |
|
| 2014 |
Tuveson DA. Abstract IA1: Modeling pancreatic cancer biology and medicine Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-Ia1 |
0.473 |
|
| 2014 |
Kultti A, Zhao C, Zimmerman S, Osgood RJ, Chen Y, Symons R, Jiang P, Thompson CB, Tuveson DA, Frost GI, Shepard HM, Huang Z. Abstract 4844: Extracellular hyaluronan accumulation by hyaluronan synthase 3 promotes pancreatic cancer growth and modulates tumor microenvironment via epithelial-mesenchymal transition Cancer Research. 74: 4844-4844. DOI: 10.1158/1538-7445.Am2014-4844 |
0.488 |
|
| 2014 |
Ponz-Sarvise M, Corbo V, Öhlund D, Oni T, Handly-Santana A, Engle D, Tiriac H, Chio C, Feigin M, Baker L, Ardito-Abraham C, Park Y, Hwang C, Elyada E, Yu K, ... ... Tuveson D, et al. 194 Pancreatic ductal organoids as a new platform for drug discovery European Journal of Cancer. 50: 63. DOI: 10.1016/S0959-8049(14)70320-X |
0.722 |
|
| 2014 |
Carapuça E, Gemenetzidis E, Feig C, Tuveson DA, Kocher H. Su1907 Developing Drug Combinations to Co-Target Pancreatic Cancer and Its Supporting Stroma Gastroenterology. 146: S-498. DOI: 10.1016/S0016-5085(14)61796-0 |
0.502 |
|
| 2013 |
Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Oncotargets and Therapy. 7: 33-43. PMID 24379681 DOI: 10.2147/Ott.S38111 |
0.464 |
|
| 2013 |
Li NF, Gemenetzidis E, Marshall FJ, Davies D, Yu Y, Frese K, Froeling FE, Woolf AK, Feakins RM, Naito Y, Iacobuzio-Donahue C, Tuveson DA, Hart IR, Kocher HM. RhoC interacts with integrin α5β1 and enhances its trafficking in migrating pancreatic carcinoma cells. Plos One. 8: e81575. PMID 24312560 DOI: 10.1371/Journal.Pone.0081575 |
0.484 |
|
| 2013 |
Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 20212-7. PMID 24277834 DOI: 10.1073/Pnas.1320318110 |
0.429 |
|
| 2013 |
Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. Plos One. 8: e67330. PMID 23840665 DOI: 10.1371/Journal.Pone.0067330 |
0.437 |
|
| 2013 |
Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America. 110: 12325-30. PMID 23836645 DOI: 10.1073/Pnas.1300415110 |
0.431 |
|
| 2013 |
Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, Espeli M, Kraman M, McKenna B, Wells RJ, Zhao Q, Caballero OL, Larder R, Coll AP, O'Rahilly S, ... ... Tuveson DA, et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. The Journal of Experimental Medicine. 210: 1137-51. PMID 23712428 DOI: 10.1084/Jem.20122344 |
0.384 |
|
| 2013 |
Chin L, De Sauvage F, Egeblad M, Olive KP, Tuveson D, Weiss W. Recapitulating human cancer in a mouse Nature Biotechnology. 31: 392-395. PMID 23657389 DOI: 10.1038/Nbt.2575 |
0.38 |
|
| 2013 |
Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnouj A, Fendrich V, Ring J, Sipos B, Tuveson DA, Bremer C, Gress TM, Michl P. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Gut. 62: 1034-43. PMID 22677720 DOI: 10.1136/Gutjnl-2012-302577 |
0.395 |
|
| 2013 |
Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, ... ... Tuveson DA, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 62: 112-20. PMID 22466618 DOI: 10.1136/Gutjnl-2012-302529 |
0.365 |
|
| 2013 |
Barrett MT, Lenkiewicz E, Lisa E, Perez-Mancera P, Tuveson D, Aust D, Pilarsky C, Aziz M, Posner R, Ramanathan R, Velculescu V, Kramer A, Drebin J, Hoff DDV. Abstract 798: Clonal analysis and clinical translation of pancreatic adenocarcinoma genomes. Cancer Research. 73: 798-798. DOI: 10.1158/1538-7445.Am2013-798 |
0.437 |
|
| 2013 |
Oosterom I, Schultes BC, Chu CL, Galcheva-Gargova Z, Kurtagic E, Zhou H, Duffner J, Voest EE, Tuveson DA, Lolkema M. Abstract 302: Characterization of effects of M402 on EMT in pancreatic ductal adenocarcinoma. Cancer Research. 73: 302-302. DOI: 10.1158/1538-7445.Am2013-302 |
0.392 |
|
| 2013 |
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KAT, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, ... ... Tuveson DA, et al. Erratum: Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma Nature. 494: 390-390. DOI: 10.1038/Nature11864 |
0.438 |
|
| 2012 |
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, ... ... Tuveson DA, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 491: 399-405. PMID 23103869 DOI: 10.1038/Nature11547 |
0.41 |
|
| 2012 |
Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4266-76. PMID 22896693 DOI: 10.1158/1078-0432.Ccr-11-3114 |
0.427 |
|
| 2012 |
Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, ... ... Tuveson DA, et al. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 486: 266-70. PMID 22699621 DOI: 10.1038/Nature11114 |
0.469 |
|
| 2012 |
Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discovery. 2: 260-9. PMID 22585996 DOI: 10.1158/2159-8290.Cd-11-0242 |
0.429 |
|
| 2012 |
Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discovery Today. 17: 253-60. PMID 22493784 DOI: 10.1016/J.Drudis.2012.02.003 |
0.41 |
|
| 2012 |
Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Praseedom RK, Huguet EL, Jah A, ... ... Tuveson DA, et al. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. 12: 8-15. PMID 22487467 DOI: 10.1016/J.Pan.2011.12.009 |
0.395 |
|
| 2012 |
Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 142: 1079-92. PMID 22406637 DOI: 10.1053/J.Gastro.2012.03.002 |
0.386 |
|
| 2012 |
Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, Tuveson DA. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. The Journal of Experimental Medicine. 209: 437-44. PMID 22351932 DOI: 10.1084/Jem.20111923 |
0.45 |
|
| 2012 |
Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 148: 21-3. PMID 22265397 DOI: 10.1016/J.Cell.2011.12.021 |
0.364 |
|
| 2012 |
Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, Tuveson DA. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut. 61: 877-84. PMID 22157328 DOI: 10.1136/Gutjnl-2011-300850 |
0.669 |
|
| 2012 |
Caldwell ME, DeNicola GM, Martins CP, Jacobetz MA, Maitra A, Hruban RH, Tuveson DA. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene. 31: 1599-608. PMID 21860420 DOI: 10.1038/Onc.2011.350 |
0.718 |
|
| 2012 |
Schultes BC, Lolkema MP, Chu CL, Zhou H, Long A, Lockley M, Avery W, Kurtagic E, Galcheva-Gargova Z, Miller P, Duffner J, Maschek BJ, Jarlenski D, Tuveson DA, Roach J, et al. M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer. Journal of Clinical Oncology. 30: 4056-4056. DOI: 10.1200/Jco.2012.30.15_Suppl.4056 |
0.421 |
|
| 2012 |
Jodrell DI, Bapiro T, Cook N, Frese K, Jacobetz M, Neesse A, Richards F, Tuveson D. Abstract IA13: How much gemcitabine reaches the target… and does it matter? Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-Ia13 |
0.424 |
|
| 2012 |
Jones JO, Feig C, Roberts EW, Wells RJB, Tuveson DA, Fearon DT. Abstract B94: Fibroblast activation protein alpha-expressing stromal cells mediate immune suppression in the KPC mouse model of pancreatic ductal adenocarcinoma. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-B94 |
0.461 |
|
| 2012 |
Neesse A, Frese KK, Bapiro TE, Spong S, Jodrell DI, Tuveson DA. Abstract B33: Inhibition of stromal-derived CTGF sensitizes murine pancreatic adenocarcinoma to gemcitabine treatment. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-B33 |
0.491 |
|
| 2012 |
Weyden Lvd, Rust A, Perez-Mancera P, Tuveson D, Jonkers J, Mullighan C, Winton D, Adams D. Abstract SY08-01: Large-scale screens for cancer genes in the mouse Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy08-01 |
0.427 |
|
| 2012 |
Courtin A, Richards FM, Bapiro TE, Smith D, Williams M, Bramhall JL, Frese K, Tuveson DA, Jodrell DI. Abstract 3771: Capecitabine pharmacokinetics and efficacy in spontaneous tumors occurring in a genetically engineered mouse model (GEMM) of pancreatic cancer Cancer Research. 72: 3771-3771. DOI: 10.1158/1538-7445.Am2012-3771 |
0.411 |
|
| 2012 |
Tuveson DA. Abstract IA5: Developing therapeutics in mice with ductal pancreatic cancer Clinical Cancer Research. 18: IA5-IA5. DOI: 10.1158/1078-0432.Mechres-Ia5 |
0.472 |
|
| 2012 |
Perez-Mancera PA, Rust AG, Biankin AV, Wessels LFA, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ, Tuveson DA. 108 The Deubiquitinase USP9X Suppresses Pancreatic Ductal Adenocarcinoma European Journal of Cancer. 48. DOI: 10.1016/S0959-8049(12)70812-2 |
0.389 |
|
| 2012 |
Feig C, Jones JO, Wells RJ, Tuveson DA, Fearon DT. Pancreatic stellate cells are immunosuppressive modulators in pancreatic ductal adenocarcinoma Pancreatology. 12: e3-e4. DOI: 10.1016/J.Pan.2012.07.007 |
0.393 |
|
| 2011 |
Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA, Hagemann T. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. The Journal of Clinical Investigation. 121: 4685-99. PMID 22056382 DOI: 10.1172/Jci45797 |
0.437 |
|
| 2011 |
Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discovery. 1: 128-36. PMID 22043453 DOI: 10.1158/2159-8290.Cd-10-0044 |
0.674 |
|
| 2011 |
Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, Tuveson DA, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell. 147: 382-95. PMID 22000016 DOI: 10.1016/J.Cell.2011.09.032 |
0.698 |
|
| 2011 |
Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D, Elsum I, Greenfield A, Tuveson DA, Simon R, Humbert PO. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. The Journal of Clinical Investigation. 121: 4257-67. PMID 21965329 DOI: 10.1172/Jci58509 |
0.35 |
|
| 2011 |
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, ... ... Tuveson DA, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 475: 106-9. PMID 21734707 DOI: 10.1038/Nature10189 |
0.683 |
|
| 2011 |
Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology. 141: 1486-97, 1497.e1-14. PMID 21704588 DOI: 10.1053/J.Gastro.2011.06.047 |
0.462 |
|
| 2011 |
Tuveson D, Hanahan D. Translational medicine: Cancer lessons from mice to humans. Nature. 471: 316-7. PMID 21412332 DOI: 10.1038/471316A |
0.398 |
|
| 2011 |
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, ... ... Tuveson DA, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 469: 539-42. PMID 21248752 DOI: 10.1038/Nature09639 |
0.348 |
|
| 2011 |
Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 60: 861-8. PMID 20966025 DOI: 10.1136/Gut.2010.226092 |
0.434 |
|
| 2011 |
Richards FM, Courtin A, Bapiro TE, Bramhall JL, Cook N, Frese KK, Tuveson DA, Jodrell DI. Abstract 5446: The activity and pharmacokinetics of capecitabine in a mouse model (K8484) of pancreatic adenocarcinoma Cancer Research. 71: 5446-5446. DOI: 10.1158/1538-7445.Am2011-5446 |
0.331 |
|
| 2011 |
Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin M, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, ... ... Tuveson D, et al. Abstract 2805: Exome sequencing identifies frequent mutation of the SWI/SNF complex genePBRM1in renal carcinoma Cancer Research. 71: 2805-2805. DOI: 10.1158/1538-7445.Am2011-2805 |
0.38 |
|
| 2011 |
Azevedo ACP, Jiang J, Lee EJ, Gusev Y, Allard D, Tuveson DA, Calin GA, Schmittgen TD. Abstract 1179: Global increase in ultraconserved non-coding RNA expression in pancreatic adenocarcinoma Cancer Research. 71: 1179-1179. DOI: 10.1158/1538-7445.Am2011-1179 |
0.387 |
|
| 2010 |
Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 18: 499-509. PMID 21056012 DOI: 10.1016/J.Ccr.2010.10.015 |
0.508 |
|
| 2010 |
Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (New York, N.Y.). 330: 827-30. PMID 21051638 DOI: 10.1126/Science.1195300 |
0.437 |
|
| 2010 |
Grippo PJ, Tuveson DA. Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prevention Research (Philadelphia, Pa.). 3: 1382-7. PMID 21045161 DOI: 10.1158/1940-6207.Capr-10-0258 |
0.384 |
|
| 2010 |
Lolkema M, Lockley M, Zhou H, Duffner J, Kishomoto TK, Tuveson DA. Abstract LB-43: M402, a novel heparin sulphate mimetic, synergizes with gemcitabine to improve survival and reduce metastasis and epithelial-to-mesenchymal transition (EMT) in a genetically engineered mouse model for pancreatic cancer Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-43 |
0.438 |
|
| 2010 |
Travaglione V, Deyneko I, Proctor J, McGovern K, Trujillo A, Lolkema M, Tuveson D, MacDougall J. Abstract LB-374: The Hh inhibitor IPI-926 enhances tumor perfusion and nab-paclitaxel activity in a pancreatic xenograft model Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-374 |
0.504 |
|
| 2010 |
Olive KP, Jacobetz M, Gopinathan A, Goldgraben M, Ireland H, Reichelt S, Howat WJ, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson D. Abstract PR2: Therapeutic intervention targeting a Hedgehog-dependent barrier to drug delivery in pancreatic cancer Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-Pr2 |
0.494 |
|
| 2009 |
Karreth FA, DeNicola GM, Winter SP, Tuveson DA. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Molecular Cell. 36: 477-86. PMID 19917255 DOI: 10.1016/J.Molcel.2009.10.017 |
0.64 |
|
| 2009 |
DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. European Journal of Cancer (Oxford, England : 1990). 45: 211-6. PMID 19775620 DOI: 10.1016/S0959-8049(09)70036-X |
0.673 |
|
| 2009 |
Caldwell ME, Tuveson DA. Finding and killing the CRABs of pancreatic cancer. Gastroenterology. 137: 782-5. PMID 19643193 DOI: 10.1053/J.Gastro.2009.07.035 |
0.456 |
|
| 2009 |
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, ... ... Tuveson DA, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (New York, N.Y.). 324: 1457-61. PMID 19460966 DOI: 10.1126/Science.1171362 |
0.706 |
|
| 2009 |
Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. Current Opinion in Genetics & Development. 19: 4-11. PMID 19201597 DOI: 10.1016/J.Gde.2008.12.006 |
0.386 |
|
| 2008 |
Gopinathan A, Tuveson DA. The use of GEM models for experimental cancer therapeutics. Disease Models & Mechanisms. 1: 83-6. PMID 19048065 DOI: 10.1242/Dmm.000570 |
0.409 |
|
| 2008 |
Cook N, Olive KP, Frese K, Tuveson DA. K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods in Enzymology. 439: 73-85. PMID 18374157 DOI: 10.1016/S0076-6879(07)00406-5 |
0.503 |
|
| 2007 |
Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research. 67: 9518-27. PMID 17909062 DOI: 10.1158/0008-5472.Can-07-0175 |
0.478 |
|
| 2007 |
Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, Jacks T. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Research. 67: 8089-94. PMID 17804720 DOI: 10.1158/0008-5472.Can-07-2300 |
0.749 |
|
| 2007 |
Frese KK, Tuveson DA. Maximizing mouse cancer models. Nature Reviews. Cancer. 7: 645-58. PMID 17687385 DOI: 10.1038/Nrc2192 |
0.423 |
|
| 2007 |
Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Research. 67: 6075-82. PMID 17616662 DOI: 10.1158/0008-5472.Can-06-4128 |
0.502 |
|
| 2007 |
Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch R, Jacks T. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes & Development. 21: 694-707. PMID 17369402 DOI: 10.1101/Gad.1526207 |
0.658 |
|
| 2007 |
Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 11: 229-43. PMID 17349581 DOI: 10.1016/J.Ccr.2007.01.017 |
0.42 |
|
| 2007 |
Zhang J, Liu Y, Beard C, Tuveson DA, Jaenisch R, Jacks TE, Lodish HF. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood. 109: 5238-41. PMID 17317860 DOI: 10.1182/Blood-2006-09-047050 |
0.625 |
|
| 2007 |
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature. 445: 661-5. PMID 17251932 DOI: 10.1038/Nature05541 |
0.69 |
|
| 2006 |
King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, ... ... Tuveson DA, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Research. 66: 11100-5. PMID 17145850 DOI: 10.1158/0008-5472.Can-06-2554 |
0.375 |
|
| 2006 |
Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5277-87. PMID 17000660 DOI: 10.1158/1078-0432.Ccr-06-0436 |
0.425 |
|
| 2006 |
Pérez-Mancera PA, Tuveson DA. Physiological analysis of oncogenic K-ras. Methods in Enzymology. 407: 676-90. PMID 16757361 DOI: 10.1016/S0076-6879(05)07053-9 |
0.435 |
|
| 2006 |
Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood. 108: 2041-4. PMID 16720837 DOI: 10.1182/Blood-2006-01-013490 |
0.639 |
|
| 2006 |
Tuveson DA, Zhu L, Gopinathan A, Willis NA, Kachatrian L, Grochow R, Pin CL, Mitin NY, Taparowsky EJ, Gimotty PA, Hruban RH, Jacks T, Konieczny SF. Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Research. 66: 242-7. PMID 16397237 DOI: 10.1158/0008-5472.Can-05-2305 |
0.684 |
|
| 2006 |
Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, Longnecker DS, Luttges J, Maitra A, ... ... Tuveson DA, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Research. 66: 95-106. PMID 16397221 DOI: 10.1158/0008-5472.Can-05-2168 |
0.392 |
|
| 2006 |
Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Research. 66: 14-7. PMID 16397208 DOI: 10.1158/0008-5472.Can-05-3914 |
0.427 |
|
| 2005 |
Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harbor Symposia On Quantitative Biology. 70: 65-72. PMID 16869739 DOI: 10.1101/Sqb.2005.70.040 |
0.485 |
|
| 2005 |
Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Research. 65: 10280-8. PMID 16288016 DOI: 10.1158/0008-5472.Can-05-2193 |
0.658 |
|
| 2005 |
Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 8: 311-21. PMID 16226706 DOI: 10.1016/J.Ccr.2005.09.008 |
0.325 |
|
| 2005 |
Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Research. 65: 8166-73. PMID 16166291 DOI: 10.1158/0008-5472.Can-05-1650 |
0.657 |
|
| 2005 |
Denicola G, Tuveson DA. VAV1: a new target in pancreatic cancer? Cancer Biology & Therapy. 4: 509-11. PMID 15970675 DOI: 10.4161/Cbt.4.5.1781 |
0.737 |
|
| 2005 |
Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 7: 469-83. PMID 15894267 DOI: 10.1016/J.Ccr.2005.04.023 |
0.409 |
|
| 2005 |
Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Research. 65: 2412-21. PMID 15781657 DOI: 10.1158/0008-5472.Can-04-2423 |
0.383 |
|
| 2004 |
Flaherty KT, Brose M, Schuchter L, Tuveson D, Lee R, Schwartz B, Lathia C, Weber B, O'Dwyer P. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7507. PMID 28014896 DOI: 10.1200/Jco.2004.22.14_Suppl.7507 |
0.318 |
|
| 2004 |
Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. Cancer Biology & Therapy. 3: 1058-9. PMID 15640618 DOI: 10.4161/Cbt.3.11.1302 |
0.417 |
|
| 2004 |
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 119: 847-60. PMID 15607980 DOI: 10.1016/J.Cell.2004.11.004 |
0.64 |
|
| 2004 |
Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 5: 375-87. PMID 15093544 DOI: 10.1016/S1535-6108(04)00085-6 |
0.631 |
|
| 2004 |
Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. The Journal of Clinical Investigation. 113: 528-38. PMID 14966562 DOI: 10.1172/Jci20476 |
0.8 |
|
| 2004 |
Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America. 101: 597-602. PMID 14699048 DOI: 10.1073/Pnas.0307203101 |
0.642 |
|
| 2004 |
Braun BS, Gavin J, Tuveson DA, Jacks TE. In Vitro Analysis of Myeloid Proliferation Caused by Oncogenic Kras. Blood. 104: 795-795. DOI: 10.1182/Blood.V104.11.795.795 |
0.677 |
|
| 2004 |
Braun BS, van Ziffle J, Gavin J, Tuveson DA, Jacks T, Shannon K. Anemia and Ineffective Erythropoiesis Caused by Somatic RAS Mutation. Blood. 104: 3419-3419. DOI: 10.1182/Blood.V104.11.3419.3419 |
0.652 |
|
| 2004 |
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, ... ... Tuveson DA, et al. Erratum: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse (Cancer Cell (4) (437-450)) Cancer Cell. 5. DOI: 10.1016/S1535-6108(03)00335-0 |
0.699 |
|
| 2003 |
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, ... ... Tuveson DA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4: 437-50. PMID 14706336 DOI: 10.1016/S1535-6108(03)00309-X |
0.715 |
|
| 2003 |
Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & Development. 17: 3112-26. PMID 14681207 DOI: 10.1101/Gad.1158703 |
0.418 |
|
| 2003 |
Hingorani SR, Tuveson DA. In search of an early warning system for pancreatic cancer. Cancer Biology & Therapy. 2: 84-6. PMID 12673125 DOI: 10.4161/Cbt.246 |
0.404 |
|
| 2003 |
Hingorani SR, Tuveson DA. Ras redux: rethinking how and where Ras acts. Current Opinion in Genetics & Development. 13: 6-13. PMID 12573429 DOI: 10.1016/S0959-437X(02)00017-5 |
0.344 |
|
| 2002 |
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. 347: 472-80. PMID 12181401 DOI: 10.1056/Nejmoa020461 |
0.324 |
|
| 2002 |
Tuveson DA, Jacks T. Technologically advanced cancer modeling in mice. Current Opinion in Genetics & Development. 12: 105-10. PMID 11790563 DOI: 10.1016/S0959-437X(01)00272-6 |
0.694 |
|
| 2001 |
Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & Development. 15: 3243-8. PMID 11751630 DOI: 10.1101/Gad.943001 |
0.661 |
|
| 2001 |
Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 20: 5054-8. PMID 11526490 DOI: 10.1038/Sj.Onc.1204704 |
0.645 |
|
| 2001 |
Tuveson DA, Fletcher JA. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Current Opinion in Oncology. 13: 249-55. PMID 11429482 DOI: 10.1097/00001622-200107000-00007 |
0.365 |
|
| 2001 |
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410: 1111-6. PMID 11323676 DOI: 10.1038/35074129 |
0.795 |
|
| 2001 |
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. The New England Journal of Medicine. 344: 1052-6. PMID 11287975 DOI: 10.1056/Nejm200104053441404 |
0.354 |
|
| 1999 |
Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. Oncogene. 18: 5318-24. PMID 10498884 DOI: 10.1038/Sj.Onc.1203107 |
0.676 |
|
| Show low-probability matches. |
